Foreign drug companies strongly opposed against insurance pricing policy on imported drugs.

The foreign pharmaceutical corporations having their business in Korea expressed a total backlash against the MOHW insurance reimbursement price policy on the imported drugs, reducing the existing market prices of imported drugs by 40 to 80%, for which the foreign pharmaceutical community admitted it a sort of government sanctioning policy over the future introduction of new drugs and therefore...